Immunogenicity of a booster dose of a bivalent (Asp614Gly and omicron BA.4/5 variant) self-amplifying mRNA SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4/5 mRNA vaccine: a randomised phase 3 trial,The Lancet Infectious Diseases

当前位置： X-MOL 学术 › Lancet Infect Dis › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Immunogenicity of a booster dose of a bivalent (Asp614Gly and omicron BA.4/5 variant) self-amplifying mRNA SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4/5 mRNA vaccine: a randomised phase 3 trial
The Lancet Infectious Diseases ( IF 36.4 ) Pub Date : 2024-10-23 , DOI: 10.1016/s1473-3099(24)00565-6
Yusuke Okada MSc, Yuji Kumagai PhD, Iori Okura MSc, Mako Otsuki MSc, Natsuki Ishida MSc, Yasuhiro Iwama MSc, Takeshi Minamida BSc, Yukihiro Yagi PhD, Toru Kurosawa PhD, Josephine van Boxmeer MPhil, Ye Zhang PhD, Igor Smolenov MD, Prof Judd L Walson MD

We previously showed that ARCT-154, a self-amplifying mRNA COVID-19 vaccine, had improved immunogenicity and antibody persistence compared with conventional mRNA or adenovirus vector vaccines. In this study, we compared ARCT-2301, a bivalent self-amplifying mRNA vaccine (Asp614Gly and omicron BA.4/5 variant), with the bivalent Comirnaty omicron BA.4-5 vaccine, to determine whether this improved response persisted in bivalent formulations against different SARS-CoV-2 variants.

中文翻译：

二价（Asp614Gly 和 omicron BA.4/5 变体）自扩增 mRNA SARS-CoV-2 加强疫苗加强剂量与 BNT162b2 omicron BA.4/5 mRNA 疫苗的免疫原性：一项随机 3 期试验

我们之前表明，与传统的 mRNA 或腺病毒载体疫苗相比，ARCT-154 是一种自扩增 mRNA COVID-19 疫苗，具有更好的免疫原性和抗体持久性。在这项研究中，我们将二价自扩增 mRNA 疫苗（Asp614Gly 和 omicron BA.4/5 变体）ARCT-2301 与二价 Comirnaty omicron BA.4-5 疫苗进行了比较，以确定这种改善的反应是否在针对不同 SARS-CoV-2 变体的二价制剂中持续存在。

更新日期：2024-10-23

点击分享查看原文

点击收藏

阅读更多本刊新发论文